A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on
- shortening the length and reducing the symptoms of human rhinovirus infection (also
known as the common cold),
- controlling asthma symptoms, and
- lowering the risk of asthma symptoms worsening in subjects with asthma.